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Background: The aim of this study was to clarify the clinical significance of TM4SF members CD9, CD63 and CD82
in human gastric carcinoma.
Methods: By employing RT-PCR and immunohistochemistry, we studied the expression of CD9, CD63 and CD82 in
49 paired tissue specimens of normal gastric mucosa and carcinoma. All tissues were obtained from patients who
underwent curative surgery.
Results: All normal gastric epithelium and gastric ulcer tissues strongly expressed transcripts and proteins of CD9,
CD63 and CD82 as compared with corresponding controls. We found a significant correlation between CD63
mRNA level and different pM statuses (P = 0.036). Carcinomas in M0 stage revealed a stronger expression of CD63
than carcinomas in M1 stage. Expression of CD9 protein was found significantly stronger in pN0, pM0 than in
advanced pN stages (P = 0.03), pM1 (P = 0.013), respectively. We found the relationship between CD63 expression,
gender (p = 0.09) and nodal status (p = 0.028), respectively. Additionally, advanced and metastasized tumor tissues
revealed significantly down-regulated CD82 protein expression (p = 0.033 and p = 0, respectively), which correlated
with the tumor pTNM stage (p = 0.001).
Conclusion: The reduction of CD9, CD63 and CD82 expression are indicators for the metastatic potential of gastric
carcinoma cells. Unlike their expression in other tumor types, the constitutive expression of CD63 may indicate that
this factor does play a direct role in human gastric carcinogenesis.
Introduction
The TM4 superfamily (TM4SF) includes more than 20
core members and a number of additional proteins with
sequence similarities. Nearly all mammalian cells con-
tain one or more TM4SF proteins. The correct biologi-
cal functions of the TM4 superfamily could not have
been fully elucidated, but it has been reported that sev-
eral TM4SF members, such as CD9, CD63, CD81, CD82
and CD151 might be involved in cell signaling. Further-
more, recent data suggest some TM4SF members might
play roles in signal transduction pathways and to regu-
late cell activation, development, proliferation, and
motility [1]. For instance, CD9, CD82 and CD63 have
been reported to modulate the tumor progression or
metastasis [2-4]. As type III integral membrane glyco-
proteins, CD9, CD82 and CD63 have two divergent
extracellular loop domains, the larger of which contains
several conserved amino acid motifs, highly conserved
hydrophobic tetra-transmembrane domains and two
short cytoplasmic domains at the NH2 and COOH ter-
mini [5,6].
CD9 gene is located on human chromosome 12p13.3
and encodes 227 amino acids. It was described originally
as a 24-kDa surface protein of non-T acute lymphoblas-
tic leukemia cells and developing B-lymphocytes [7].
CD9 is also expressed in plasma membrane of various
cell types, including hematopoietic cells, endothelial
cells, normal epithelial cells, and several tumor cell
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demonstrated that CD9 functions as a tumor metastatic
suppressor in various cancers, including non-small-cell
lung cancers, breast cancers, and colon cancers [13-15].
The CD82 gene is located on human chromosome
11p11.2 and encodes a 2.4 kb transcript which is trans-
lated into a N-glycosylated, transmembrane protein of
267 amino acids [3,16]. It attracted considerable atten-
tion as a tumor metastasis suppressor gene in prostatic
cancer. Recent and retrospective studies have shown
that decreased wild type CD82 expression could be a
useful marker for metastatic and has invasive potential
in some human tumor types, including pancreatic,
breast, colorectal, bladder and oral cancers [17-23].
CD63 is isolated from human chromosome 12p12-q13
has been implicated in phagocytic and intracellular lyso-
some-phagosome fusion events. CD63 plays a role in
the regulation of cell motility in melanoma cells and is
involved in cell adhesion events [24], and strongly
expressed on the cell surface in the early stage of malig-
nant melanoma but weakly in the more advanced stages
[25]. The data of our previous study demonstrated the
expression of CD82 was correlated significantly with the
metastatic status of human thyroid carcinoma. However,
CD63 expression pattern did not correlate with any
tumor staging [26].
The biological functions of these factors in human
gastric carcinoma are still not clearly understood. In this
retrospective study on staged human gastric carcinoma
tissues, we investigated the expression of these three
TM4SF members to determine whether they correlate




No patient was required the perioperative neo/adjuvant
chemotherapy in this study. From each patient, one
representative primary tumor block, including tumor
centre and invasion front as well as tumor-associated
non-neoplastic mucosa, were examined by immuno-
histochemistry.
Forty-nine patients were included in this study who
with up to stage IV gastric carcinoma at the Department
of General, Visceral and Vascular Surgery of Martin-
Luther-University Halle-Wittenberg between 1994 and
2002. This study was approved by the local committee
of medical ethics and all patients gave written consent.
Tumor tissues were staged according to the Tumor-
node-metastasis (TNM) staging classification (UICC-
AJCC 1997). The clinical characteristics of the patients
with gastric carcinoma are presented in Table 1.
For employing Semi quantitative RT-PCR and immuno-
histochemistry, resected gastric tissues were immediately
frozen in liquid nitrogen and maintained at -80°C. Frozen
sections at 6 μm were cut by using Microm cryostat sys-
tem (Microm International GmbH, Walldorf, Germany)
on a cryostat and control sections were hematoxylin-eosin
stained.
Semi quantitative RT-PCR
To prevent crosscontamination of samples and carry-
over contamination, laser-assisted microdissection was
performed for subsequent isolation of genomic RNA (P.
A.L.M.
® system, Bernried, Germany). Total RNA from
fresh tissue samples, SW480 cell line (human colon car-
cinoma cell line) and FTC-133 (human follicular thyroid
carcinoma cell line) was extracted by using the TRIZOL
reagent (Invitrogen, Carlsbad, USA) according to the
manufacturer’s protocol. First-strand cDNA synthesis
was performed with 1 μgo ft o t a lR N Au s i n gac D N A
synthesis kit (Gibco, Munich, Germany) following the
manufacturer’s protocol at 42°C for 30 min followed by
enzyme inactivation at 95°C for 5 min.
For PCR amplification, a 2 μl aliquot of the reaction
mixture was used. The following PCR primer pairs were
used to amplify a 800 bp amplicon of CD9 (sense 5’-
TGCATCTGTATCCAGCGCCA-3’/antisense 5’-CTC
AGGGATGTAAGCTGACT-3’; a 598 bp encoding
CD82 (sense 5’- GCA GTC ACT ATG CTC ATG G-3’/
antisense 5’-TGC TGT AGT CTT CGG AAT G-3’) and
a 347 bp amplicon for CD63 (sense 5’- CCC GAA AAA
CAA CCA CAC TGC-3’/antisense 5’-GAT GAG GAG
GCT GAG GAG ACC-3’) ,a n da4 6 7b pa m p l i c o n sf o r
the housekeeping genes GAPDH (sense 5’-TGG TGA
A G GT C GG T GT G AA C - 3 ’/antisense 5’-TTC CCA
T T CT C AG C CT T GA C - 3 ’). All PCR reactions were
performed with AmpliTaq (for CD9, CD82 and 18 S)
and AmpliTaq-Gold (for CD63) (Amersham, USA). The
PCR profile was as follows: 30 sec at 94°C, 45 sec at
(CD9: 60°C; CD82:58°C; CD63:56°C, GAPDH:60°C) and
30 sec at 72°C. CD9, CD82, CD63 and GAPDH con-
sisted of 30 sec at 94°C, 30 sec at 60°C, 45 sec at 72°C,
and a final elongation step for 7 min at 72°C. 20 μl PCR
products were run visualized in a 1.5% agarose gel (Peq-
Lab), photographed with Kodak Image System 440 cf
and electronically evaluated with “TL100” Total Lab
software (Nonlinear Dynamics, UK). The expression of
positive control was set as 100% (Figure 1), the expres-
sion levels of all investigated specimens were classified
in comparison to the positive controls (for CD9 and
CD63: SW480; and for CD82: FTC-133-CD82 overex-
pressing clone) grey scale. The densitometric values
obtained for CD9, CD82 and CD63 bands in a given
tumor tissue sample were divided by the corresponding
v a l u eo fG A P D H ,a n dt h er a t i ow a sr e f e r r e dt oa st h e
gene expression ratio for each gene. The evaluated value
of a specimen between 0%- 20% was defined as
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Page 2 of 8Table 1 Relation between CD9, CD63 and CD82 expression and various prognostic factors
clinicopathological
characteristics
No. of patients CD9 CD63 CD82
transcript protein transcript protein transcript protein
Gender avarage p-value average p-value avarage p-value average p-value avarage p-value average p-value
Male 29 83.10 0.707 3.11 0.238 112.56 0.616 4.40 0.009 87.90 0.66 3.19 0.54
Female 20 82.31 4.06 110.12 3.00 80.47 2.64
Age
≤65 20 81.10 0.867 3.78 0.477 113.94 0.842 4.14 0.323 83.12 0.884 3.32 0.551
>65 29 83.97 3.27 109.83 3.54 86.00 2.74
Tumor stage
T1 and T2 13 85.14 3.75 114.23 3.73 91.38 4.00
T3 11 89.98 0.79 3.43 0.215 107.64 0.462 3.17 0.81 78.34 0.866 2.39 0.033
T4 15 81.97 2.17 101.82 3.54 87.85 1.81
Nodal status
N0 5 74.61 5.60 105.13 4.25 67.82 4.40
N1 13 79.73 0.556 2.91 0.03 106.47 0.774 4.23 0.028 77.85 0.23 2.88 0.094
N2 15 94.81 (N2 and N3)2,571 111.05 2.77 109.72 2.33
N3 3 86.71 114.77 6.00 64.94 1.67
metastatic status
M0 11 90.68 0.403 4.64 0.013 121.84 0.036 3.90 0.137 90.40 0.77 4.35 0
M1 18 85.46 2.17 100.24 3.19 95.17 1.23
Differentiation
G1 and G2 5 81.93 4.20 118.89 5.25 83.67 3.75
G3 24 85.77 0.82 3.05 0.624 108.33 0.432 3.31 0.105 87.57 0.691 2.23 0.304
G4 8 86.09 3.50 114.50 3.67 71.39 3.10
pTNM stage
I and II 12 79.10 4.08 109.53 3.91 73.67 4.06
III 7 105.38 0.379 3.88 0.209 112.67 0.897 2.67 0.482 106.32 0.418 3.88 0.001
IV 19 69.66 2.50 96.80 3.68 46.35 0.95
Lauren’s classification
intestinal type 12 69.30 0.105 3.42 0.538 109.93 0.719 4.50 0.06 80.17 0.773 3.80 0.535


























































































8“Negative"; 20%-50% “Decreased"; 50-75% “Moderate";
75% and more “Positive”.
Immunohistochemistry
Immunohistochemistry wasp e r f o r m e db yu s i n gD a k o
Coverplates (Dako, Germany) on frozen tissue sections of
6 μm thickness. After 20 min fixation in a 1:4 mixture of
3% H2O2 in ice cold 90% Methanol, the slides were
washed in phosphate-buffered saline (PBS) and pre-incu-
bated for 10 min at room temperature with PBS - 1%
bovine serum albumin (BSA), which was also used as a
diluent for the antibodies. Successive sections were incu-
bated overnight at 4°C with the CD9 (mouse monoclonal,
MEM-61, abcam] at the dilutions of 1:200, the antibody
against human CD82 (mouse monoclonal, clone 50F11,
BD Pharmingen) at the dilutions of 1:300 and the antibody
against human CD63 (mouse monoclonal, NKI/C3, Novo-
castra Laboratories Ltd) at the dilutions of 1:200, respec-
tively. Negative control sections were only exposed to the
secondary antibody and processed as described above.
After 3 × 10 min washes in PBS, sections were incubated
for 30 min with a 1:1000 dilution of biotinylated goat anti-
mouse secondary antibody (Dako-anti-IgG-Kit) followed
by incubation with an avidin-biotin-peroxidase complex.
Specific immunostaining was visualized with a 15% diami-
nobenzidine (DAB) chromogenic solution (Dako, Aarhus,
Denmark). Finally, sections were lightly counterstained
with Mayer’s hematoxylin. Tissue sections from a normal
human tonsil (from patient who underwent tonsilectomy)
were used as positive controls.
Interpretation of immunostaining scoring
We employed the planimetric measurement features by
using the “PALM RoboSoftware 3.2” (PALM MicroLaser
Systems) software to determine the immunostaining
intensity. This software allows the user to encircle areas
for calculation (μm
2). The sum of all immunopositive
cell squares (μm
2) was calculated and compared with
the total section area. Subjective interpretation of immu-
nohistochemistry was minimized by using a modification
of the German immunoreactive score (IRS) method
(Table 2). The immunohistochemical scoring was
performed by two independent reviewers. A consensus
opinion was used to score the rare cases for divergent
opinions. We assigned an intensity score (0 to 3+) and a
distribution score (estimated percentage of reactive
cells) to describe staining of study cases. The criteria for
scoring staining intensity were listed in table 2: To cal-
culate the IRS, we assigned the following points for
staining distribution: 1, 1-25% of cells; 2, 26-50%; 3, 51-
75%; and 4, 76-100%. These points were then multiplied
b yt h es t a i n i n gi n t e n s i t ys c o r et og i v ear a n g eo fp o t e n -
tial IRSs from 0-12. Weak staining was defined as an
IRS that ranged from 1 to 3, and moderate/strong stain-
ing was 4-12.
Statistical analysis
Sigmaplot 8.0 was applyed for all graphs calculations.
Comparisons of the distributions of three TM4SF mem-
bers expression for different groups were performed
using the Wilcoxon-Mann-Whitney test (for two
groups) or the Kruskal-Wallis test (for more than two
groups). P-values of < 0.05 were considered to indicate
statistical significance.
Results
CD9, CD82 and CD63 gene expression in gastric cancer
tissues analyzed by RT-PCR
All normal gastric epithelium and gastric ulcer tissues
strongly expressed transcripts of CD9, CD63 and CD82.
Out of 49 gastric cancers tissues investigated, 17 carcino-
mas (34.7%) were evaluated as CD9 positive and 32 carci-
nomas (65.3%) as CD9 negative. Furthermore, 17
carcinoma tissues (34.7%) were evaluated as CD82 posi-
tive and 32 carcinomas (34.7%) as CD82 negative. Only 6
carcinomas (12.2%) were evaluated as CD63 negative, but
43 carcinomas (87.8%) were CD63 positive (Figure 1).
CD9, CD82 and CD63 protein expression analyzed by
immunohistochemistry
All normal gastric epithelium and gastric ulcer tissues
were strongly expressed immunostaning of CD9, CD63
and CD82. Out of 49 gastric cancer tissues were stu-
died by employing immunohistochemistry, 18 cases
(36.7%) were classified as CD9 positive. In these cases,
Table 2 Immunohistochemical scoring
A: Staining
intensity
B: Precentage of positive Tumor
cells
C: score
0 = no staining 0 = 0% positive cells
1 = weak staining 1 =< 10% positive cells
2 = moderate
staining
2 = 10 - 50% positive cells A × B =
C
3 = strong staining 3 = 51 - 80% positive cells
4 => 80% positive cells Figure 1 1.5% Agarose gel electrophoresis of RT-PCR-amplified
CD9, CD63, CD82 and GAPDH. +: positive control; No.1-13: gastric
carcinoma tissue samples
Chen et al. World Journal of Surgical Oncology 2011, 9:43
http://www.wjso.com/content/9/1/43
Page 4 of 8immunostaining of CD9 was intense and uniform on
the cell-surface membrane (Figure 2). 31 cases (63.3%)
revealed decreased CD9 expression, and the immunos-
taining in most of these tumors was heterogeneous.
The immunohistochemical results were agreed with
those of RT-PCR and 98.0% of the specimens coin-
cided directly.
Further investigations demonstrated 21 CD82 positive
cases (42.9%) and 27 CD82 negative cases (57.1%) (Fig-
ure 2). These results correlated with those of RT-PCR
and 91.8% of the specimens coincided directly.
We identified 30 cases (61.2%) positive for CD63 and
19 CD63 negative cases (38.8%) (Figure 2). These results
correlated with those of RT-PCR. However, only 73.5%
of the specimens coincided directly.
Relationship between CD9, CD82 and CD63 gene
expression and various prognostic factors
The relationship between CD9, CD63 and CD82 gene
expression and various prognostic factors are shown in
table 1. Analysis of CD9, revealed no statistically signifi-
cant correlations between gene expression and age, gen-
der, tumor status, differentiation, pTNM stage and
Lauren classification. Contrary, CD9 protein level was
associated with lymph node status (p = 0.03) as well as
with metastatic status (p = 0.013); Compared with 7
(63.6%) of N1 stage patients and 11(68.8%) of N2-3
stage patients, no N0 stage patients showed negative
gene expression. Furthermore, only 4(36.3%) of M0
stage patients had negative gene expression compared
with 13(72.2%) of M1 stage patients.
Figure 2 CD9, CD63 and CD82 immunohistochemical staining patterns. A,B,C: CD9, CD63 and CD82 expression in normal gastric mucosa; D,
E, F: CD9, CD63 and CD82 expression in Gastric tumor tissue (non-metastasized); G,H,I: CD9, CD63 and CD82 expression in Gastric tumour tissue
(metastasized); J,K,L:CD9, CD63 and CD82 expression in Lymph tissue (submucosa layer).
Chen et al. World Journal of Surgical Oncology 2011, 9:43
http://www.wjso.com/content/9/1/43
Page 5 of 8The relationship between CD63 and various prognos-
tic factors were associated with gender (p = 0.09) and
nodal status (p = 0.028). Six male patients (20.7%)
showed negative gene expression, and 13 female patients
(65%) were CD63 negative. Furthermore, only one (25%)
patients with N0 and 3 (27.3%) patients with N1
demonstrated negative gene expression compared with 9
(69.2%) of N2-3 stage patients.
In contrast, CD82 protein level was associated with
tumor status (p = 0.033); metastatic status (p = 0) and
pTNM stage (p = 0.001). 5 T1 patients(38.5%) were
CD63 negative as compared with 6 T2 (54.5%) and 8 T3
(53.3%) patients. Analysis of metastatic status revealed
that only 1 M0 patient (9%) and all M1 patients were
CD63 negative. With respect to pTNM stage, only 2
stage I and II patients (22.2%) and no stage III patients
were CD63 negative as compared with 10 stage IV
(100%) patients.
Discussion
In the present study, we investigated the expression of
the three TM4SF members, CD9, CD63, and CD82. We
demonstrated that CD9 protein levels were inversely
associated with lymph node metastasis of gastric carci-
noma. Furthermore, the reduction of CD9 protein was
associated with distant metastasis of gastric cancer. Our
results suggest that decreased levels of CD9 are strongly
associated with an increased risk of recurrence, espe-
cially in patients with N0 nodal status and M0 meta-
static status. These findings are consistent with previous
reports demonstrating that reduced levels of CD9 corre-
lated with poor prognosis of patients with breast and
non-small cell lung cancers [13,27].
CD63 was originally described as a marker in the early
stages of melanoma progression since it was highly
expressed in radial growth-phase primary melanomas
[28]. And it had been reported that it was strongly
expressed on the cell surface in the early stage of malig-
nant melanoma but weakens in the more advanced
stages [25]. There is still no report showing that it is
associated with other type of cancer. We demonstrated
for the first time that mRNA levels of CD63 were asso-
ciated with distant metastasis and CD63 protein corre-
lated lymph node status. Taken together, these results
suggested that decreased levels of CD63 were associated
with a high pTNM staging and CD63 may served as a
marker for metastatic potential of gastric cancer. Addi-
tionally, we found that CD63 proteins levels were lower
in female that in male group. However, the reasons for
that are still unclear and require further investigations.
CD82 has been identified as a metastasis suppressor
gene [29]. Although the precise mechanisms for regula-
tion of CD82 remain unclear, down-regulation rather
than mutation is the most common mechanism in the
progression of many cancers [14,17,22,30-33]. In our
study, we demonstrated that the decreased levels of
CD82 protein were strikingly associated with the tumor
status and the distant metastasis. Furthermore, CD82
protein expression was inversely associated with the
pTNM stages. These results were consistent with pre-
vious findings showing a direct correlation between
reduction of CD82 gene expression and bad prognosis
in patients with prostatic cancer and non-small cell lung
cancer [3,34].
The mechanism of TM4SF mediated inhibition of can-
cer invasion and metastasis remains unclear. Cell adhe-
sion and cell migration play important roles in a variety
of physiological and pathological processes such as
embryonic development, cancer metastasis, blood vessel
formation and remodeling, and inflammation. Because
of the specific structure of TM4SF [13], the extracellular
domains can mediate specific protein-protein interac-
tions with laterally associated proteins and unknown
ligands, where they modulate integrin-dependent cell
adhesion activities. The association of TM4SF members
with various integrins is well documented. These mem-
bers have little, if any, effect on the binding of integrins
to their ligands or on integrin-mediated static cell adhe-
sion to the extracellular matrix [35]. Instead, they regu-
late post-ligand binding events, including intergrin-
mediated adhesion strengthening, a process whereby
cells become increasingly resistant to detachment from
immobilized integrin ligands [36].
The participation of TM4SF members in metastatic
ability, morphological alternations and increased motility
of tumor cells is often integrin-dependent. Previous
reports demonstrated that the effects of CD63 on moti-
lity were similar to those reported for CD9 and both
proteins were reported to associate with b1a n db3
integrins and to be identical with motility-related pro-
tein [36]. And previous work has also shown that the
TM4SF members affect process such as cell prolifera-
tion, apoptosis and tumor metastasis. Various members
of TM4SF associate with signaling enzyme, including
protein phosphatases, conventional PKCs and type II
phosphatidylinositol 4-kinase. CD82, as a suppressor of
tumor cell metastasis, have the clearest mechanisms of
the three members. the mechanisms of CD82 inhibits
cell motility and invasiveness may because it can active
the FAK-Src-p130Cas-CRKII pathway during cell migra-
tion and lead to DOCK180-dependent activation of
Rac1 membrane ruffling and directional cell migration,
with the p130Cas-CRKII complex functioning as a key
“molecular switch” [37]. The association of CD82 with
EWI2, another molecular that suppresses cell ruffling
and migration [38], could also potentially contribute to
the suppressor function of CD82. And CD82 attenuated
signaling by the epithermal growth factor receptor
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lig- and-induced dimerization and endocytosis [39]. This
provides another avenue for CD82-mediated inhibition
of cell migration and invasion.
For further understanding of the potential role of
TM4SF in metastasis, we can go on to collect informa-
tion of follow-up, and analyze the relationship of CD9,
CD63 and CD82 with the Days after surgery. And in the
future, we can also establish a gastric cancer cell model
overexpressing CD9, CD63 or CD82, by using a plasmid
vector. Then we can use the MTT test and Motility test
to clarify relationship between wild type and the CD9,
CD63 or CD82 overexpressing cells in cell proliferation
and cell motility.
The classification of gastric cancers according to CD9,
CD63 and CD82 expression might be useful in identify-
ing patients for whom intensive adjuvant therapy is war-
ranted. It is conceivable that testing tumors for TM4SF
expression, in combination with other molecular and
biochemical assays, may improve the prognostic evalua-
tion of gastric cancer patients, and enhance the clini-
cian’s ability to prospectively identify patients who will
have early disease recurrence and who require adjuvant
chemotherapy. Many researches have shown that CD82
signalling may powerfully influence the development of
metastasis. Although a significant amount of work is
still required to uncover the mechanisms of action and
regulation of CD82 in metastasis suppression, recent
observations suggest that this metastasis suppressor
gene and other members of this group of genes, like
CD9 and CD63 will be of tremendous interest to the
drug discovery industry for the development of thera-
peutics agents. It is conceivable that investigates the
tumors for TM4SF expression, in combination with
other molecules, may improve the prognostic evaluation
of gastric cancer patients, and enhance the clinician’s
ability to prospectively identify patients who will develop
early disease recurrence and who require adjuvant
chemotherapy.
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